Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label, multicenter, phase II trial investigating the combination
of thoracic radiotherapy plus Durvalumab in patients with locally advanced, unresectable
NSCLC (stage III) that are unfit for chemotherapy (e.g. due to age and/or frailty).
Phase:
Phase 2
Details
Lead Sponsor:
IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest